SCHEMBL4723359

SCHEMBL4723359

CCCCNc1csnn1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.44
TLR8 Q9NR97 3/20 0.41
MGLL Q99685 2/20 0.40
HCAR3 P49019 2/20 0.38
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
DNM2 P50570 2/20 0.35
SOAT1 P35610 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
HRH4 Q9H3N8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4722200 0.88
Acetaldehyde SCHEMBL28641262 0.85 MGLL (0.41) KMT2AMGLLHCAR3DNM2SOAT1
SCHEMBL6198331 0.71 KMT2A (0.52) KMT2AMGLLALDH1A1SMN1; SMN2ATM
SCHEMBL4720826 0.69 TLR8 (0.41) TLR8HCAR3ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL24632695 0.68 TLR8 (0.47) TLR8HCAR3ALDH1A1SMN1; SMN2DNM2
SCHEMBL10244651 0.67 HTT (0.51) MGLLALDH1A1SMN1; SMN2ATML3MBTL1
SCHEMBL11667263 0.67
SCHEMBL5109811 0.65 TLR8 (0.41) TLR8HCAR3ALDH1A1SMN1; SMN2ATM
SCHEMBL4722363 0.65 TLR8 (0.41) TLR8HCAR3ALDH1A1SMN1; SMN2DNM2
SCHEMBL11664173 0.64 MMP3 (0.46) KMT2ATLR8ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 KMT2A 3345/4885TLR8 1678/4885MGLL 3716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.